@putrinolab.bsky.social
@sinaibrain.bsky.socialReposted by @putrinolab.bsky.socialA NEW STUDY from @mountsinainyc.bsky.social's David Putrino @putrinolab.bsky.social, Jacqueline Becker, et al. found that people w/ #LongCOVID who used a noninvasive magnetic therapy headset show improved cognitive function & mood. Press Release 🧠www.mountsinai.org/about/newsro...
@sinaibrain.bsky.socialReposted by @putrinolab.bsky.socialCHECK OUT the Full Study in Brain Communications
"Microtesla magnetic therapy for cognitive impairment in long COVID: a randomized pilot study"
- Alexandra Canori, David Putrino @putrinolab.bsky.social, Jacqueline Becker, et al.
🧠academic.oup.com/braincomms/a...
@mountsinainyc.bsky.social
@putrinolab.bsky.socialJust a reminder (many seem to need it): A failed Paxlovid trial in #LongCOVID does not erase the validity of all the careful work demonstrating SARS-CoV-2 persistence LC, it just shows us that drugs that target acute infection don’t always work on chronic infection. That’s it.
@longcovidanswers.bsky.socialReposted by @putrinolab.bsky.socialCould Some Long COVID Patients Need Someone Else’s #Mitochondria?
Prof @putrinolab.bsky.social discusses different patterns of mitochondrial dysfunction in #LongCOVID &research into whether healthy donor mitochondria could one day be explored for patients with severe dysfunction.
@putrinolab.bsky.socialfantastic team from Fareon - these analyses are tricky and the amount of data are overwhelming. Our team is incredibly fortunate to have such great collaborators that are pushing urgently for this technology to be accessible to patients ASAP. Onward!
www.globenewswire.com/news-release...
/end
@putrinolab.bsky.socialtest this technology in other diagnoses where we believe neuroinflammation to be driving cognitive symptoms: #concussion, #TBI, #stroke, #mecfs and chronic #lyme. These are incredibly promising results and I'm so grateful to the brilliant team at SomaScan as well as the
9/
@putrinolab.bsky.socialfrom non-responders (NR). We have a long way to go before this is an approved treatment for cog impairment in people with #LongCOVID, but the next phase of this project is to initiate a large-scale, multi-site clinical trial of this technology. In parallel, we are starting to
8/
@putrinolab.bsky.socialProteins involved in things like increasing autophagy, reducing inflammation, boosting mitochondrial function and these 17 proteins really popped in the analysis that was done by the team, with a 17-protein response score clearly physiologically differentiating MMT responders 7/
@putrinolab.bsky.socialThat really appeared to be associated with clinical response to the MMT therapy (figure below). What was particularly cool about these proteins was that they weren't 'junk' proteins, they were proteins that were legitimately associated with the MMT mechanism of action. 6/
@putrinolab.bsky.socialFirst finding of note was the responder analysis: encouragingly, in our cohort from the first paper we saw many more responders (R) in the treatment group than the sham group (80% vs. 30%). But then as we dug into the proteomics, we noted that there were 17 different proteins 5/
@putrinolab.bsky.socialSomascan uses synthetic DNA probes as molecular detectors, this method can precisely measure over 10,000 proteins simultaneously in blood plasma. This technique is very sensitive to changes in protein expression between timepoints that may be driving improvements in symptoms. 4/
@putrinolab.bsky.socialcontrol arm. What was cool about this study was that we also captured plasma at different stages of the trial and in collaboration with Somascan #proteomics, we took a look at differences in proteomic readout in the MMT trial participants (preprint👇)
www.medrxiv.org/content/10.6...
3/
@putrinolab.bsky.socialcontrolled pilot, we showed that MMT was a well-tolerated and feasible intervention that could be deployed remotely in the home. In addition to this, we saw some early signal that it may also be having an effect on patient cognition in the active treatment arm vs. those in the 2/
@putrinolab.bsky.socialDelighted to announce some new progress on our #LongCOVID trial with Fareon and their first-in-human microtesla magnetic therapy (MMT) device. As you may recall, we pre-printed the safety/feasibility work not too long ago:
www.medrxiv.org/content/10.6...
In this triple-blind placebo-
1/
@putrinolab.bsky.socialHowever, I hope this megathread adequately explains my position and I hope that people can understand that my team’s North Star is always working rapidly to make more viable treatment options available for people suffering with these terrible diagnoses. Keep up the fight 💪🏼 /end
@putrinolab.bsky.socialto budge. There is a lot of work to be done and we get there much faster together. Also apologies for the length of this and for the fact that I’ve pretty much used up my entire social media allowance for the week on writing this monster so I’m unlikely to respond to much… 36/
@putrinolab.bsky.socialare no other valid viewpoints” probably isn’t seeing the issue clearly at the moment. We need people of differing viewpoints to come together and to be willing to discuss literature, concede issues and move the field forward rather that digging into one position and refusing 35/
@putrinolab.bsky.social@putrinolab.bsky.socialyou roll up your sleeves and get to work in making the most specific diagnosis that you can:
#LongCOVID, #MECFS, chronic #lyme, babesiosis, #EDS, #sjogrens, #hashimotos, #MECFS that has been worsened by a COVID infection, #LongCOVID AND #MECFS, reactivated EBV from a COVID,
33/
@putrinolab.bsky.socialPAIS and IACCI may seem like “lumper mindset”, but the first step to splitting appropriately is creating a common framework from where you start to split. In my mind, that’s what PAIS/IACCI is: once you suspect that this is the diagnostic cluster that you’re working within, 32/